Physician profile
Christopher Alan Hebert
NPI 1912966045
$101,515.22
in general payments reported to CMS, 2019-2025
35 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $12K · 2021: $11K · 2022: $16K · 2023: $31K · 2024: $9,411 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $2,389 · Consulting Fee: $1,890 · Travel and Lodging: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,035.00 |
| Food and Beverage | $2,388.78 |
| Consulting Fee | $1,890.00 |
| Travel and Lodging | $1,511.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $60,003.44 | 2019-2024 | Ultomiris |
| Mallinckrodt Enterprises LLC | $18,843.03 | 2019 | |
| Nxstage Medical, INC. | $17,683.93 | 2019-2025 | Nxstage System One, Nxstage Cartridge Express |
| La Jolla Pharmaceutical Company | $1,683.50 | 2019-2023 | Giapreza |
| Vifor Pharma, INC. | $535.86 | 2019-2023 | Veltassa |
| Astrazeneca Pharmaceuticals Lp | $303.07 | 2019-2023 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $298.11 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $260.63 | 2020-2023 | Acthar |
| Horizon Therapeutics Plc | $237.77 | 2019-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $229.60 | 2020-2025 | Velphoro, Novalung System |
| Opko Pharmaceuticals, LLC | $168.09 | 2020-2023 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $143.09 | 2019-2023 | Jynarque |
| Amgen INC. | $140.12 | 2019-2023 | Tavneos |
| Pfizer INC. | $137.57 | 2019-2024 | |
| Travere Therapeutics, INC. | $120.55 | 2019-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $95.13 | 2019 | |
| Ani Pharmaceuticals, INC. | $85.44 | 2022-2024 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $74.35 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $52.89 | 2023 | Cystadrops |
| Daiichi Sankyo INC. | $51.42 | 2023 | Injectafer |
| W. L. Gore & Associates, INC. | $50.36 | 2023-2024 | Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Tag Conformable Thoracic Endoprosthesis |
| Potrero Medical, INC. | $38.29 | 2021 | |
| Glaxosmithkline, LLC. | $38.24 | 2021-2022 | |
| Chiesi USA, INC. | $33.09 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $28.65 | 2023 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $27.71 | 2024 | Lupkynis |
| Renalytix Ai, INC. | $24.01 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Shield Therapeutics INC | $20.26 | 2022 | |
| Eagle Pharmaceuticals, INC. | $18.04 | 2023 | |
| Merck Sharp & Dohme LLC | $17.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.04 | 2025 | Jardiance |
| Medtronic, INC. | $15.91 | 2024 | Symplicity G3 |
| Paratek Pharmaceuticals, INC. | $13.90 | 2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $13.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.